Insmed opened higher at $113.60, compared with its previous close of $111.59. In the last trading session, the stock traded between $111.97 and $116.37. It showed an upward intraday trend.
An investment of $100 made 5 years ago in Insmed is now worth
$ 375.21
giving a profit of
$ 275.21 (275.21%)
Note: Past profits do not guarantee future returns.
Rating from 21 Analysts
Today's Change
+$1.54 (+1.38%)
Day High
$116.37
Day Low
$111.97
Day Open
$113.60
Prev Close
$111.59
Volume
19,67,302
1W Return
19.10%
1M Return
-2.12%
3M Return
9.63%
6M Return
-16.22%
1Y Return
-32.24%
Market Cap ($ Mn)
24,705
PE Ratio
-
PB Ratio
34.16
PEG Ratio
-
ROE
-192.35%
ROCE
-64.91%
EPS (TTM)
$-0.06
1 Week
19.10%
1 Month
-2.12%
3 Months
9.63%
6 Months
-16.22%
9 Months
-28.32%
Insmed shares fall as CFO Bonstein to exit Oct 30; 2026 guidance held
Insmed Inc. shares dropped nearly 7% following CFO Sara Bonstein's departure announcement. Bonstein will leave the role on October 30 after nearly seven years with the company. Full-year 2026 revenue guidance reaffirmed at $1.25-$1.40 billion for BRINSUPRI. FDA granted Priority Review for ARIKAYCE with a target action date of January 28, 2027.
25 days agoInsmed reaffirms FY26 revenue guidance for Brinsupri and Arikayce
Insmed reaffirms FY26 revenue guidance of $1.25 billion to $1.40 billion for BRINSUPRI. ARIKAYCE revenue guidance maintained at $450 million to $470 million for FY26. Company cites operational excellence and momentum for reaffirming targets.
25 days agoInsmed 15-year return: $1,000 investment grows to $27,361
Insmed delivered an average annual return of 24.7% over 15 years. A $1,000 investment from 15 years ago is now worth $27,361.95. The stock outperformed the market by 11.06% on an annualized basis. Current market capitalization stands at $25.54 billion.
1mo agoFDA accepts Insmed's Arikayce sNDA for MAC lung disease
FDA accepted Insmed's sNDA for Arikayce for MAC lung disease treatment. Priority Review granted with a PDUFA target action date of January 28, 2027. Application supported by Phase 3b ENCORE study meeting primary endpoints. Insmed plans to review data with Japan's PMDA in Q4 2026 for label expansion.
1mo agoTruist Securities raises Insmed price target to $195 on Buy
Truist Securities analyst Danielle Brill reiterates a Buy rating on Insmed while raising the price target to $195 from $185. The move highlights positive institutional sentiment toward the NASDAQ-listed biopharma firm.
2mo agoInsmed shares deliver 41.43% annualized return over five years
Insmed has generated a 41.43% average annual return over the last five years, outperforming the market by 29.76%. A $1,000 investment from five years ago is now valued at $5,573.37 at the current price of $131.95. The company’s market capitalization stands at $28.82 billion, illustrating significant long-term wealth creation for shareholders through compounded growth.
2mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $540.00 | +1.95% | $1,36,868.94M | 31.55 | |
| $61.07 | +2.12% | $1,31,639.87M | 14.39 | |
| $222.76 | +4.01% | $88,933.81M | - | |
| $818.77 | +0.68% | $82,808.76M | 19.64 | |
| $897.85 | +0.68% | $56,462.20M | 38.99 | |
| $371.56 | -0.48% | $40,792.43M | 65.60 | |
| $190.27 | +0.82% | $40,781.71M | - | |
| $56.49 | -1.40% | $35,253.15M | 26.24 | |
| $65.93 | +1.71% | $29,357.11M | 32.37 | |
| $37.52 | +1.10% | $27,101.56M | - | |
| $116.80 | -0.06% | $23,675.13M | 15.85 | |
| $174.00 | -25.13% | $23,282.77M | 39.98 |
An investment of $100 made 5 years ago in Insmed is now worth
$ 375.21
giving a profit of
$ 275.21 (275.21%)
Note: Past profits do not guarantee future returns.
